Deirdre Lyons Head of Specialty Community Gynaecology Imperial College Healthcare NHS Trust

- Learning Objectives
- How to recognise most common conditions
- How to investigate if required
- What questions to ask
- How to assess
- How to initiate treatment
- When to refer

- Important
- History
- Itchy
- Painful
- Soreness
- Intermittent/ Constant
- 'Rash'
- Red/ White
- Scaly
- Previous treatments
- Associated conditions

- Examination Important to examine
- Evidence of lesions
- Where are the areas of concern?
- Labia Majora
- Labia Minora size
- Vestibule
- Red/ White/ Scaly
- Single/ Multiple lesions
- Pain versus not
- Creases versus not
- Lymph Nodes

- Vulvo-vaginal problems are among 10 leading disorders encountered by primary care clinicians.
- Benign lesions of the vulva are mentioned in three categories :
 - 1. Epithelial conditions.
 - 2. Benign neoplastic disorders.
 - 3. Dermatologic disorders.
- VIN
- Cancer vulva

- Epithelial Conditions
- Lichen simplex .
- Contact Dermatitis
- Lichen sclerosis.
- Lichen planus,
- Erosive lichen planus.

Vulval Disease – Lichen Simplex

Lichen simplex chronicus "The scratch that itches"

- Chronic eczematous inflammation that results in thickened skin often associated with excoriation and fissures.
- Itch Scratch Itch Cycle
 Often leads to difficulty sleeping
 Scratching may lead to secondary infection

Vulval Disease – Lichen Simplex



Vulval Disease – Lichen Simplex



Vulval Disease – Lichen Simplex Chronicus

Differential Diagnosis LSC

Diseases that cause itching

- Psoriasis
 - More sharply demarcated
 - May include extra-genital locations
- Candidiasis
 - Wet mount or yeast culture
- Lichen sclerosus
 - No scaly appearance
 - May be concurrent condition
- Infestations (lice & scabies)

Vulval Disease – Lichen Simplex Chronicus

Clinical Findings LSC

PHYSICAL EXAMINATION:

Thick, lichenified skin so labia are enlarged,

rugose +/- edematous

Bilateral or unilateral

Localized to generalized

Color - variably pink, red, violaceous to ruddy brown; often a white appearance will be present when there is a thick keratin layer deposited on the surface of the epithelium

Secondary changes - erosions, ulcer, oozing, fissuring, honey-colored or serosanguineous crusting

Vulval Disease – Lichen Simplex Chronicus

Etiology LSC

LSC develops in several itchy skin conditions: Atopic dermatitis (eczema) Contact dermatitis Lichen sclerosus

Contact dermatitis can start this condition or be the main long-term promoting factor

Vulval Disease – Lichen Simplex and Contact Dermatitis



LSC develops in several itchy skin conditions: Atopic dermatitis (eczema) Contact dermatitis Lichen sclerosus

Contact dermatitis can start this condition or be the main long-term promoting factor Vulval Disease – Lichen Simplex Chronicus -Treatment

Lichen Simplex – nonspecific measures

Improve Skin Barrier Function
 Stop Excessive Hygiene

 Avoid irritants (perfumes, dyes)

 Tepid Soaks

 Soothing, promotes circulation, cleans

 Daily Skin Protection

 "Band-aid" effect (zinc, Vaseline, veg. oil)

 Identify and treat co-existing conditions

Vulval Disease – Lichen Simplex Chronicus -Treatment


- Remove irritant/ contact allergen if possible
- Break itch-scratch cycle
- Look at various aspects of cleaning etc.
- Bland emollients
- Cetraben
- Steroid ointment –
- Most potent Clobatesol (Dermovate) –
- Topically sparingly b.d. for 8 weeks, then in decreasing dosage
- Dermol washes

Common Vulvar Contactants

ALLERGENS

Benzocaine (Vagisil) Preservatives Neomycin Latex condoms Chlorhexadine (K-Y) Lanolin (A&D ointment) Perfume Nail Polish IRRITANTS

Soaps/cleansers Sweat, urine, feces Creams (alcohol) Douches Medications – TCA, 5FU Spermicides Panty liners



Tips: Vulvar Contact Dermatitis

Irritation is the commonest cause History of contact difficult to elicit

Loss of epidermal barrier from - rash or loss of estrogen increases susceptibility to contact dermatitis

Suspect: allergic if sudden onset of rash irritant if persistent rash

- Treatment/ Management
- Remove irritant/ allergen if known
- Bland emollients
- Dermol washes
- Steroids if required
- Barrier creams



Lichen Sclerosus Introduction

- Common chronic vulvar disease
- Inflammation present
- Age range from childhood to elderly (bimodal distribution)
- Previously termed et atrophicus, now called lichen sclerosus

- Chronic progressive disease which constrict and destroy the normal genital anatomy.
- Longer term, labia minora are lost ,labia majora flatten, clitoris can become inverted .
- Found on the vulva of postmenopausal women
- Can involve all the genital area from mons to anal area.
- Risk of malignant progression 6%



Location of Lichen Sclerosus on the Vulva and Adjacent Areas

Labia	100%
Clitoris	70.4%
Perineum	67.9%
Buttocks	32.3%
Perianus	32.1%
Crural area	8.6%
Urethra	3.7%

Lorenz B. Kaufman RH. Kutzner SK. Lichen sclerosus. Therapy with clobetasol propionate. Journal of Reproductive Medicine. 43(9):790-4, 1998

- Can be asymptomatic
- Most common symptom is prirutis
- Can be severe/ intolerable/ interfere with sleep
- Pruritis ani
- OTHER SYMPTOMS
- Burning
- Soreness
- Dyspareunia
- Pain with defaecation
- Constipation

Signs

- Hypopigmentation
- Ivory white papules or plaques
- Cigarette paper appearance
- Cellophane-like sheen to surface
- Hour glass-figure of eight appearance
- Patchy or generalized
 - Vulva, perineum, perianal
 - No vaginal involvement

Signs Secondary Changes

- Fusion of labia minora
- Scratching yields open areas causing erosions
- Urinary retention
- Tearing

Whitening Fusion




Loss of Labia Minora



Differential Diagnosis

- Vitiligo
- Lichen planus
- Lichen simplex chronicus
- Vulvar intraepithelial neoplasia (squamous and nonsquamous)
- Psoriasis
- Scarring from laser surgery
- Graft versus host disease
- Tinea



Lymphocytic infiltrate under the band

TREATMENT

- Thorough assessment
- Biopsy if any concerns about VIN/ cancer
- Treat any superimposed infection i.e. yeasts
- General Care measures –
- Avoid tight occlusive clothing
- Bland emollients
- 100% cotton underwear
- No soaps on vulva can use Dermol washes

Treatment of Lichen Sclerosus

 Superpotent steroid ointment (clobetasol propionate 0.05%)
 – Twice daily in a thin, invisible film for 1 month then daily for two months

• Maintenance

- May require Clobatesol twice a week
- Decrease to Clobatesone? Or less potent steroid
- Aim of treatment to treat symptoms and to halt destruction of labia/ vulva by lichen sclerosis
- ??Decrease risk of transformation to VIN

- Other treatments
- Topical Tacrolimus
- Oral Steroids rarely required
- Side effects
- Intralesional injections steroids
- Retinoids
- Anti-malarial agents chloroquine
- Oral in intralesional

- Surgical Treatment
- Limited role
- Healing
- Recurrence
- Surgical Division of mucosal adhesions helpful in clitoral phimosis
- Surgical division of introital narrowing or labia if unable to pass urine

Vulval Disease – Lichen Planus

Lichen Planus

- T-cell mediated autoimmune response to an unknown antigen
- Histology and morphology resemble other hyperimmune conditions
- May be found with ulcerative colitis, alopecia areata, vitiligo, morphea, dermatomyositis, LS, and myasthenia gravis

Vulval disease – Lichen Planus

Erosive lichen planus

Vulval Disease – Lichen Planus

Lichen Planus Disease Course

- Erosive mucosal LP typically chronic course with waxing and waning
- Progression to vulvovaginalgingival scarring is common
- SCC is recognized risk but rare
 Estimated to be between 1% and 2%
- Nonresponsive lesions should be biopsied.


Vulval Disease – Lichen Planus

- Lichen planus can affect oral/ vaginal area
- Importance of examining oral cavity in patient's suspected of lichen planus
- Goal of treatment is relieve symptoms and prevent disease progression and complications
- Remission induction and maintenance
- Can usually be treated with topical agents
- Oral agents for severe cases


Vulval Disease – Lichen Planus

- Topical Steroids potent first line therapy
- Clobatesol 0.05 ointment
- Initially topically twice a day
- May require maintenance
- Can require topical tacrolimus
- Intravaginal steroid

Vulval Disease – Erosions and Ulcers



- Superficial or deep epidermis
- Not past basal layer



- Always secondary
- Full thickness extending into dermis or deeper

Vulval Disease – Erosions


Erosions

Common	Uncommon	Rare
ExcoriationFissures	 Allergic contact dermatitis 	 Hailey-Hailey disease
Lichen simplexHerpes simplex	Post-coital fissuresHerpes zoster	 Extramammary Paget dis.
Candidiasis Erosive lichen	 Stevens Johnson syndrome 	 Toxic epidermal Necrolysis
sclerosus	Pemphigus	
 Erosive lichen planus 	PemphigoidCicatricial pemphigoid	
ImpetigoIrritant contact	 Pemphigoid gestations 	
dermatitis	 Eroded malignancy Plasma cell vulvitis. 	

Vulval Disease - Ulcers


Ulcers

Common	Uncommon	Rare
 Aphthous ulcers, idiopathic 	 Primary syphilis (chancre) 	 Granuloma inguinale
 Aphthous ulcers 2° to infection or inflammatory disease Crohn's disease HSV in immunosuppressed 	 Trauma, accidental and self- induced Ulcerated malignancy Pyoderma gangrenosum 	 Chancroid Behçet's disease



Vulval Disease - Ulcers

Vulvar Ulcers - Diagnostic Algorithm



Two Types of VIN

VIN (usual) (Warty-Basaloid)

- HPV associated
 HPV 16 most common
- Often multifocal
 - Associated with CIN, VaIN, AIN
- Mean age 30
- Increasing incidence
- 3-10% develop SCC


VIN (Differentiated) (Simplex)

- Not HPV associated
- Often unifocal
- Associated with longstanding LS
- Average age 67
- 2-10% of VIN
- Most diagnosed adjacent to or in follow-up of SCC

VIN: Clinical Presentation

van Seters et. al. Gynecol Oncol 2005;97:645-651

- Based on review of 3322 published patients
- Symptomatic: 64%
 - Vulvar pruritis, burning, superficial discomfort, dyspareunia
- Dx made on finding visible lesion: 30%
- Multifocal: 49%
- Multicentric: 32%
- Cigarette Smoking: 84% in New Zealand Study



- Treatment of VIN
- Surgical excision for solitary lesions
- Wide local excision with 0.5 1cm margin
- /Skinning vulvectomy for large areas or multifocal disease
- Laser excision and Plasmajet excision
- Topical Imiquimod as primary treatment vs adjunctive

Outcomes of 63 women with Warty-Basaloid VIN followed without treatment Jones RW et al. Obstet. Gynecol. 2005;106:1319-26

Course variable

- 47 (75%) regressed before tx
- 10 (16 %) progressed to invasive ca before tx
- 6 (10 %) persistent disease
 - 5 young women being followed with tx
 - 1 refused tx >20 years

Treatment outcomes: Warty-Basaloid VIN Jones RW et al. Obstet. Gynecol. 2005;106:1319-26

- Recurrent/persistent disease after treatment
 - Laser vaporization: (39%)
 - Excision: (34%)
 - Margins positive: 50%Margins negative: 15%
- Recurrent / persistent disease after treatment
 - 50% if followed up to 13.7 years
 - Most required 2nd tx within 5 years of initial tx
 - Age a factor in need for repeat treatment
 - Age • 24%
 - Age >30 36%

Treatment of VIN with 5% Imiquimod Cream

- Immune response modifier
 - Stimulates secretion of cytokines including interferon and and IL-12
 - Effective in treatment of condylomata accuminata
- 10 Studies / 99 Patients with VIN
 - Complete response: 48.5%
 - Partial response (> 50% reduction): 28.3%
 - No cases of invasive cancer during tx or f/u
- Toxicity
 - Local Itching, burning; less common, induration, excoriation, HA, myalgia, flu-like syndrome
- <u>Off label use</u>

Le T, Menard C, Hicks-Boucher W. et.al. Gynecol Oncol 2007;106:579-584

Invasive Ca after Treatment for Warty-Basaloid VIN

Jones RW et al. Obstet. Gynecol. 2005;106:1319-26

- 17 of 312 women treated for VIN developed invasive cancer at least one year after treatment
 - -9 at site of initial tx
 - Median 2.4 years (range 1.1-7 years)
 - 8 at different site
 - Median 13.5 years (range 3-16 years)

Vulval Disease – VIN and Cancer – Imperial Audit

• Review 2002 – 2012

• Obtained from Histology database

 Reviewec with regards to diagnosis, outcomes, 'other ' conditions

Results

- 66 patients underwent investigation biopsy/excision
- 8 cases of benign HPV change
- 58 patients had high-grade dysplasia (VIN)
 - 10 (17%) cases were differentiated type VIN
 - 48 (83%) had usual type VIN
 - 27 (47%) had recurrent disease
 - 3 (5%) went onto develop invasive carcinoma
 - 40 (69%) had multicentric dysplasia

Demographics


Characteristics	n	%
Age (years) mean range	44 21-86	
Nulliparous	27	59%
Multiparous	18	40%
Smoking	18	28%
Alcohol	10	15%
Immunosuppression	19	29%
Preexisting vulval abnormalities	13	20%

Van Seters et al – quotes mean of 46

Demographics


Immunosuppression

- HIV positive
- Renal Transplant
- Renal/Pancreatic transplant
- Immunomodulators
- Steroids



Prior Vuval Abnormality

- Lichen Sclerosis Lichen Planus
- ■Psoriasis ■Warts
- HSV Other




Referral

Symptoms / Signs (59 patients)

none

- vulval lesion (+/- other symptoms)
- vulval pruritis, soreness, pain (or combination)








93% had symptoms OR a lesion or BOTH

Referral

• 35 (63%) had abnormal smears on referral



Differentiated VIN


- 10/58 (17%)
 - Average age 56 (range 35-86)
 - No smokers
 - Half were immunosuppressed (4 HIV+, 1 HSV)
 - All 5 patients had multicentric disease
 - 6 had multifocal disease
 - 4 had recurrent disease
 - Intervals of 1, 6, 16 years to recurrence
 - Range of histology :
 - 6 VIN3
 - 1 VIN2, 1 melanocytic change with atypia
 - 1 microinvasive
 - 1 invasive carcinoma at referral-lichen sclerosis
 - Treatment
 - 7 had excisional treatments (average #1.6 (range 1-3))
 - 2 patients had imiquimod and 1 vulvectomy

Multicentricity

Multicentric disease 40 /58 (69%) VIN & CIN (2 areas) 23 /58 (57%) VIN & VAIN/AIN (2 areas, excluding CIN) VIN & CIN & AIN/VAIN (3 areas) VIN & CIN & AIN & VAIN (all 4 areas) N = 2N = 1538% 50% N = 20 7% N = 3

Treatment Method

• 63 patients received some form of treatment or required excisional biopsy



Recurrent VIN

- 27 (47%) + 2 incomplete excisions
 - Range of number of treatments 2-7 (mode 2)
 - Average time to recurrence or development of multicentric disease was 3.2 years (range <1-20 years)
- 5 microinvasive (9%)
 - 2 had VIN2/3 following prior excision for microinvasion

3 (5%) had invasive disease

- Average age 54 (range 33-86)
 - Included 2/4 of lichen sclerosis patients (differentiated type)
 - Had multiple VIN diagnoses, including VIN3
 - All had 1-5 previous excisions, 1 failed IMQ
 - All invasive disease was treated with vulvectomy

Vulval Disease

- Thank you for your attention
- What questions would you like to ask